TheraRadar
← Back
Data updated: Jun 28, 2026

NOVELGENIX THERAPS

Generics

NOVELGENIX THERAPS is a generic drug manufacturer focused on Immunology.

2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

NOVELGENIX THERAPS's Key Drugs

NOVELGENIX THERAPS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

NOVELGENIX THERAPS's Recent FDA Approvals

New NDA/BLA approvals for NOVELGENIX THERAPS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

NOVELGENIX THERAPS's Therapeutic Areas

NOVELGENIX THERAPS's approved drugs and pipeline span 1 therapeutic area, led by Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 100%
1 drugs

NOVELGENIX THERAPS's Top Competitors

NOVELGENIX THERAPS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

NOVELGENIX THERAPS Pipeline Snapshot

Active clinical trials for NOVELGENIX THERAPS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling